Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients

Table 3

BMI-based subgroup analysis of sociodemographic and clinical characteristics in the olanzapine-treated group ().

	Normal weight ()	Overweight ()	Obesity ()		Multicomparison
Age (years)				0.303	—
Gender (F/M)	29/21	19/15	8/6	0.982	—
Body weight (kg)				<0.001
BMI				<0.001
Physical activity index^a				0.887	—
Smoking (Y/N)	15/35	8/25	4/10	0.847
Drinking (Y/N)	11/39	5/28	1/13	0.393	—
Dosage (mg/d)^b				0.087	—
Duration of olanzapine use (year)				0.892	—
Duration of illness (year)				0.585	—
PANSS				0.429	—

^aPhysical activity . ^bOlanzapine medication dosages were transformed to chlorpromazine equivalent dosages. Comparison of sociodemographic and clinical characteristics among the normal weight, overweight, and obesity subgroups.